Spyre Therapeutics, Inc. (SYRE) Earnings Call Transcript & Summary

Good morning, and welcome to the 2021 Annual Meeting of Stockholders of Aeglea BioTherapeutics. Our host for today's call is Aeglea's President and Chief Executive Officer, Anthony Quinn. [Operator Instructions] I will now turn the call over to your host. Dr. Quinn, you may begin.

Thank you, operator, and good morning, everyone. It's a pleasure to welcome you to our Annual Meeting of Stockholders. The meeting is now called to order. I would like to introduce the following members of the Board of Directors who are with us this morning: Sandy Mahatme, Ivana Liebisch, Bryan Lawlis, Alison Lawton, Sara Brownstein. I would also like to introduce our Principal Accounting Officer, Steven Weber, who is with us this morning. Natalie Hairston from American Election Services will be acting as inspector of elections for this meeting, and I will serve as the Chairman. I also want to introduce Ryan Mitteness of Fenwick & West, our legal counsel, who will act as secretary of the meeting and keep the minutes; and John Cummins of PricewaterhouseCoopers, our independent registered public accountants. We will now conduct the formal business matters of the meeting. April 13, 2021, was fixed by the Board of Directors as the record date for the proposals to be voted on at this meeting. Only holders of the company's common stock as of the close of business on the record date are entitled to receive notice of and to vote at this meeting. I present to this meeting an affidavit of Broadridge Financial Solutions attesting that a notice of meeting, together with a proxy statement and proxy, were mailed on or about April 22, 2021, to each holder of the company's common stock as of the close of business on the record date. The affidavit of mailing of the notice will be attached to the minutes of this meeting. A certified list of the holders of the issued and outstanding shares of common stock of the company as of the close of business on the record date is available by clicking the Materials link at the bottom right corner of your screen. And this list will be available for inspection during this meeting by any stockholder and will be filed with the records of the company. Broadridge Financial Solutions has examined the proxies received and reports that 43,198,827 shares or 88% of the total shares of common stock of Aeglea BioTherapeutics entitled to vote are represented by proxies or in person at this meeting. A majority of the votes entitled to be cast are represented at this meeting either in person or by proxy. A quorum is therefore present, and the meeting may now proceed. I will now review the agenda and voting procedures. We have 2 proposals in which the stockholders will be voting. Proposal #1 is the election of 2 Class II directors, each to serve a 3-year term, which will expire at the 2024 Annual Meeting of Stockholders. And Proposal #2 is the ratification of the appointment of our independent registered public accounting firm. If you previously returned your proxy or voted by phone or through the Internet and you do not wish to vote your proxy or change your vote, you do not need to vote at this meeting. Your vote has already been included in the proxy count. If you did not return a proxy or you wish to change your vote, you may do so by clicking the voting link at the bottom right corner of the screen. We'll give you some time to submit your ballots, if necessary, once we open the polls shortly. So Proposal #1 is the nomination and election of 2 Class II directors. The Board of Directors has nominated each of Russell Cox and Ivana Liebisch to be elected as directors of the company for the next 3 years and until his or her successor is duly elected and qualified. Our bylaws require that a stockholder provide advanced notice of their intent to nominate persons as director. No such notice was received. Accordingly, I declare the nominations for directors closed. Proposal #2 is to ratify the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for the fiscal year ending December 31, 2021. Because no further business is scheduled to come before the stockholders, it is now approximately 9:05 a.m. Central Time on June 8, 2021, and the polls are now open. If you did not return a proxy or wish to change your vote, you may do so by clicking the voting link at the bottom right corner of your screen. I'm going to now pause for 20 seconds to allow time to vote. [Voting]

It is now approximately 9:06 a.m. Central Time on June 8, 2021, and I declare that the polls for each matter voted upon at this meeting closed. The vote required for Proposal #1 to elect the Class II directors is a plurality of the votes cast, which means that the 2 individuals nominated for election to the Board of Directors at the meeting receiving the most affirmative for votes of the shares present or represented at this meeting will be elected. So based on preliminary vote totals, each of the nominees has been elected. Russell Cox and Ivana Liebisch are the 2 individuals who received the most votes of shares present and entitled to vote. The vote required to approve Proposal #2 to ratify the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for the fiscal year ending December 31, 2021, is an affirmative for vote of the majority of the shares present or represented at this meeting. So based on preliminary vote totals, PricewaterhouseCoopers has been ratified as Aeglea BioTherapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2021, by the requisite majority. This concludes the business portion of the meeting. There being no other business to conduct, I hereby declare the business portion of the meeting adjourned. At this time, we will answer any questions submitted from our stockholders that are germane to the meeting. If there are any other matter of concern to a stockholder and not answered at this meeting, such matters will be raised separately after the annual meeting by contacting Investor Relations at [email protected]. We have now concluded the question-and-answer session. I'd like to thank you all very much for attending our Annual Meeting of Stockholders. And I hereby declare the meeting adjourned. Ladies and gentlemen...

Ladies and gentlemen, this concludes the 2021 Annual Meeting of Stockholders of Aeglea BioTherapeutics. You may now disconnect.